Our latest research and evaluations is published regularly in:
- 19 June 2017
New TGA indication for empagliflozin
Empagliflozin is now TGA-approved for reducing cardiovascular deaths in patients with type 2 diabetes with established CVD. Find out what this means in practice.
- 19 June 2017
Statins revisited – appropriate patient selection and management are key
The use of statins in primary care remains suboptimal. Find out more about appropriate prescribing to minimise CV risk.
- 16 June 2017
Be Medicinewise Week: Medicine misuse can happen to anyone
Find out more about NPS MedicineWise's 7th annual Be Medicinewise Week
- 7 June 2017
Evaluation: GP survey results for Chronic pain program
Has management of chronic pain in general practice changed?
- 6 June 2017
Dose confusion with paracetamol/ibuprofen combinations
Avoid potential confusion about new fixed-dose combinations of paracetamol with ibuprofen.
- 20 April 2017
Quick primer on idarucizumab and NOAC-associated bleeding
What is idarucizumab (Praxbind), and why was it developed? When is idarucizumab prescribed, and when is it not?
- 19 April 2017
Idarucizumab (Praxbind) for dabigatran (Pradaxa) reversal: what you should know
Idarucizumab is an emergency reversal agent for dabigatran. Learn about appropriate follow-up after use of idarucizumab.
- 1 March 2017
Why tackle COPD now?
1.4 million Australians live with COPD and it is Australia's fifth leading cause of death. Find out more about the background to the NPS MedicineWise COPD program.
Contact our media team
If you are a journalist seeking comment on a story or more information on any of our programs or campaigns please contact the NPS MedicineWise media team
on 02 8217 8667.
For urgent media requests outside of office hours, please call 0419 618 365. If your request is not urgent you can also email an enquiry.
Publications & Programs
Australian Prescriber is an independent peer-reviewed journal that provides critical commentary on drugs and therapeutics for health professionals.
Peak stories have included the top 10 most expensive drugs, eradication of Hepatitis C, drug seeking behaviours in people and more.
RADAR provides health professionals with timely information on new drugs, medical tests and changes to listings on the Pharmaceutical Benefits Scheme and Medicare Benefits Schedule.
Peak stories have included warfarin, campaigns urging doctors to seeing health reps, and treating Hepatitis C.